Hualing Pharmaceuticals issued a notice to non-registered shareholders on September 26, 2024, announcing the publication of the 2024 interim report. The report in both Chinese and English versions can be accessed on the company's and Hong Kong Stock Exchange websites. The company encourages shareholders to read the report through the website and provides options for shareholders who have difficulty receiving or accessing the electronic version via email to apply for a free printed report. In addition, the company also reminds non-registered shareholders that if they wish to receive company communications in accordance with the Listing Rules, they should provide their email address to the intermediary institutions holding their shares. The company will send printed company communications according to the shareholders' instructions until December 31, 2024, or until the shareholder requests a change in instructions.

Hualing Pharmaceuticals issued a notice to non-registered shareholders on September 26, 2024, announcing the publication of the 2024 interim report. The report in both Chinese and English versions can be accessed on the company's and Hong Kong Stock Exchange websites. The company encourages shareholders to read the report through the website and provides options for shareholders who have difficulty receiving or accessing the electronic version via email to apply for a free printed report. In addition, the company also reminds non-registered shareholders that if they wish to receive company communications in accordance with the Listing Rules, they should provide their email address to the intermediary institutions holding their shares. The company will send printed company communications according to the shareholders' instructions until December 31, 2024, or until the shareholder requests a change in instructions.